Resolving Autoimmune Disease Through Phosphatase Control
Innovation in Phosphatase-Targeting Biologics
Resolving Autoimmune Disease Through Phosphatase Control
Innovation in Phosphatase-Targeting Biologics
DISEASE PROGRAMS
RHEUMATOID ARTHRITIS
RHEUMATOID ARTHRITIS
RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a highly prevalent, systemic autoimmune disease marked by joint inflammation and destruction. RA affects over 1 million patients in the United States, with as many as 40% of patients unable to find symptom relief with standard therapies alone. Knoubis Bio is focused on development of novel biologics that specifically target disease-driving cells in the RA joint while also providing immunoregulation to help patients take control of their symptoms.
LUPUS
RHEUMATOID ARTHRITIS
RHEUMATOID ARTHRITIS
Cutaneous lupus erythematosus (CLE) is an autoimmune disorder characterized by severe rashes, skin fibrosis and scarring, as well as decreases in quality of life and risk of progression to systemic manifestations of lupus. Knoubis Bio is developing non-immunosuppressive biologics that target key cells involved in the skin inflammatory response.